A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy
This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's urine. Hypothesis: In patients with progressive IgA nephropathy an intravenous infusion of 1000 mg of rituximab on Day 1 and Day 15 and Days 168 and 182 is superior to conventional therapy in reducing 24 hour proteinuria, and slowing progression of chronic kidney disease.
Stanford is now accepting new patients for this trial.
- dietary supplement : Omega-3 Fatty Acid Fish Oil Supplement
- drug : ACE/ARB
- drug : Intravenous Rituximab
Phase: Phase 4
Ages Eligible For Study: